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R E S EARCH ART I C L EGENE THERAPYGene Therapy Prolongs Survival and Restores Function
in Murine and Canine Models of Myotubular Myopathy
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4Loss-of-function mutations in the myotubularin gene (MTM1) cause X-linked myotubular myopathy (XLMTM), a fatal,
congenital pediatric disease that affects the entire skeletal musculature. Systemic administration of a single dose of a
recombinant serotype 8 adeno-associated virus (AAV8) vector expressing murine myotubularin to Mtm1-deficient
knockout mice at the onset or at late stages of the disease resulted in robust improvement in motor activity and con-
tractile force, corrected muscle pathology, and prolonged survival throughout a 6-month study. Similarly, single-dose
intravascular delivery of a canine AAV8-MTM1 vector in XLMTM dogs markedly improved severe muscle weakness and
respiratory impairment, andprolonged life span tomore than1year in theabsenceof toxicityor ahumoral or cell-mediated
immune response. These results demonstrate the therapeutic efficacy of AAV-mediated gene therapy for myotubular my-
opathy in small- and large-animal models, and provide proof of concept for future clinical trials in XLMTM patients.an
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 INTRODUCTION
Seminal clinical studies have recently shown that gene replacement ther-
apy based on localized or systemic administration of adeno-associated
viral (AAV) vectors has significant potential for the treatment of human
monogenic diseases, such as retinal degeneration, metabolic disorders, or
hemophilia (1–4). AAV vectors are excellent candidates to also treat neu-
romuscular diseases; however, to date, trials in patients with muscular
dystrophies have been limited to local intramuscular injections with no
obvious clinical benefit (5–8).
X-linkedmyotubularmyopathy (XLMTM;OMIM310400) is a fatal
nondystrophic disease of skeletal muscle that affects about 1 in 50,000
male births. Patients typically present with marked hypotonia, generalized
muscle weakness, and respiratory failure at birth (9). Survival beyond the
postnatal period requires intensive support, often including gastrostomy
feeding andmechanical ventilation. XLMTM results from loss-of-function
mutations in the myotubularin 1 gene (MTM1) (10), which encodes the
founder member of a family of 3-phosphoinositide phosphatases acting
on the second messengers phosphatidylinositol 3-monophosphate [PI(3)P]
and phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2] (11, 12). Although
myotubularin is expressedubiquitously, loss of this enzymeprimarily affects
skeletal muscles. Myogenesis occurs, but muscle fibers throughout the1Department of Rehabilitation Medicine, School of Medicine, University of Washington,
Campus Box 358056, Seattle, WA 98109, USA. 2Institute for Stem Cell and Regenerative
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Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. 6Depart-
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www.Sciencbody are hypotrophic and display structural abnormalities, with asso-
ciated weakness (13). No effective therapy exists for XLMTM.
Animal models of the disease currently exist in zebrafish, mouse,
and dog (13–15). Genetic disruption ofMtm1 in mice causes profound
abnormalities in skeletal muscle mass, structure, and function, regard-
less of whether expression is knocked out constitutively or only in a
muscle-specific fashion (13, 16). The murine phenotype resembles hu-
manXLMTM,with similar pathology and earlymortality. Local injection
of anMtm1 AAV vector rescued muscle function in the muscle-specific
knockout (KO)model, indicating that restorationof functionalmyotubularin
could ameliorate the disease phenotype (17). In the canine model—
Labrador Retrievers carrying an X-linkedMTM1missense mutation—
muscles from affected males exhibit strongly reduced synthesis and
altered localization of myotubularin, likely due to sequestration and deg-
radation of the misfolded protein. The clinical picture closely resembles
that of patients with comparably severe mutations, and survival does not
normally exceed 4 months (15).
Here, we report the long-term therapeutic potential of systemic ad-
ministration of an AAV8 vector expressing the myotubularin gene under
the control of amuscle-specific promoter in themurine and caninemodels
of XLMTM. InMtm1-deficient mice, tail vein injection of AAV8-Mtm1
at a dose of 1013 vector genomes per kilogram (vg/kg) at onset or at later
stages of the disease corrected muscle pathology and prolonged survival
throughout the 6-month study. In 9-week-oldMTM1-deficient dogs, in-
travascular administration of AAV8-MTM1 at the same dose was well
tolerated, rescued the skeletal muscle pathology and respiratory function,
and prolonged life for more than 1 year.RESULTS
Systemic Mtm1 delivery prolongs survival of
Mtm1-deficient mice
MyotubularinKOmice (Mtm1KO)displaymuscle pathology by 3weeks
of age (fig. S1) and survive on average less than 2 months, as previouslyeTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 1
R E S EARCH ART I C L E
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 described (13, 18). To correct the MTM1 deficiency, we developed a
muscle-tropic serotype 8 AAV vector expressing the Mtm1 comple-
mentary DNA (cDNA) under the control of a muscle-specific desmin
promoter (AAV2/8-pDesmin-Mtm1, abbreviated AAV8-Mtm1). The
vector was produced in human embryonic kidney (HEK) 293 cells by
a tritransfection-based system, formulated for in vivo injection, and
used to treat two groups of KO mice at different stages of disease evo-
lution, at the early onset of the pathology (3 weeks of age) or at the late
stage of the disease when mortality occurs (5 weeks of age) (Fig. 1A). A
single tail vein injection of AAV8-Mtm1 at a dose of 3 × 1013 vg/kg in
Mtm1 KO mice at 3 weeks (KO Early; n = 8) conferred long-term sur-
vival and nearly normal growth on 100% of the treated animals (Fig. 1B
and movie S1). The same dose was administered to severely affected
mice at 5 weeks (KOLate; n= 11), when 20%of the animals had already
died. All treated mice remained viable and gained body mass over a
6-month observation period, except for a single 5-week-old mouse that
died 1 day after injection (Fig. 1, B and C). Consistent with their robust
appearance, skeletal muscles grew to normal size in vector-injected
Mtm1 KO mice. In both the early- and late-treated cohorts, each of
the seven individual muscles analyzed gained mass, reaching >70% of
the mass of wild-type muscle at 6 months (Fig. 1D).
Analysis ofmyotubularin expression byWestern blotting in individ-
ual muscles at sacrifice demonstrated that intravenous delivery of
AAV8-Mtm1 reconstituted efficient myotubularin synthesis in skeletal
muscles throughout the body.Myotubularin levels ranged between one-
and fivefold greater than wild-type values in most skeletal muscles.
There was nomajor difference between the early and late treatment co-
horts, except for two peaks of >15-fold expression in the soleus muscle
of early-treated KOmice and >40-fold expression in the tibialis anterior
of late-treated KO mice (Fig. 1E). Myotubularin was highly overex-
pressed in the heart (720 ± 153 times the endogenous level 6 months
after treatment) (fig. S2C). The AAV8-Mtm1 average vector copy num-
ber (VCN; corresponding to viral genomes per diploid genome) in early-
and late-treated mice was 0.72 ± 0.1 and 0.87 ± 0.1 in the tibialis anterior
muscle and 1.67 ± 0.4 and 3.33 ± 2.1 in the biceps brachii muscle, respec-
tively. VCN in the heart and liver ranged between 1.17 to 5.14 and 80 to
223 viral genomes/diploid genome, respectively, consistent with the
known tropism of AAV8. At necropsy, the heart of AAV-treated KO
mice showed the presence of some focal lesions with scar tissue and a
modest cellular infiltrate, although these lesions did not affect survival
in any of the treatedMtm1 KO animals.
Mtm1 gene therapy corrects muscle pathology and function
in myotubularin-deficient mice
The muscles of Mtm1 KO mice treated with AAV8-Mtm1 underwent
sustained amelioration of pathological features. Figure 2 shows repre-
sentative histology from the tibialis anterior and biceps brachii limb
muscles of untreated, 5-week-old Mtm1 KO mice and AAV-treated,
6-month-old KOmice, demonstrating normalized cross-sectional fiber
size and intracellular architecture, as revealed by hematoxylin and eosin
(H&E) andNADH(reduced formof nicotinamide adenine dinucleotide)–
tetrazolium reductase (NADH-TR) staining (see fig. S2 for additional
information).Morphometry of tibialis anterior and biceps brachii myo-
fibers from 5-week-oldMtm1 KOmice gave a mean diameter of 15.9 ±
0.8 mm and 17 ± 0.7 mm, respectively, with many fibers below 20 mm,
compared to 28.7 ± 0.8 mmand 24.3 ± 1.2 mm forwild-typemice (Fig. 2B
and fig. S2A). Six months after treatment with AAV8-Mtm1, the abun-
dance of extremely small-diametermyofiberswas eliminated, and the sizewww.Sciencdistribution approached that of wild-typemuscles in both cohorts. In ad-
dition, myofibers of treated mice displayed a reduced frequency of cen-
trally localized nuclei, a diagnostic feature of centronuclear myopathies
like XLMTM (fig. S2B).
Distinctive features ofmyotubularin-deficientmyofibers include ab-
errant accumulations of mitochondria (13) and a marked deficiency of
transverse tubules (T-tubules), invaginations of the plasma membrane
perpendicular to the length of themyofiber that are critical for excitation-
contraction coupling and muscle function (14, 18). Untreated Mtm1
KO mice showed abnormal localization of proteins associated with
theT-tubule system, including thedihydropyridine1a receptor (DHPR1a),
a voltage-gated Ca2+ channel, and dysferlin, a transmembrane protein
involved inCa2+-dependentmembrane repair (Fig. 2A, arrows).Treatment
with AAV8-Mtm1 corrected abnormal mitochondria distribution and
cellular mislocalization of DHPR1a and dysferlin in all mice from both
early- and late-treated cohorts, indicating that XLMTM-associated
pathology can be reversed well after the onset of the disease.
Structural muscle abnormalities are mirrored by severe functional
deficits in Mtm1 KO mice. To measure the effect of gene therapy on
muscle function,weused theopen-field actimeter, globalmuscle strength,
and isolated limb strength assays. Open-field actimeter measurements
showed that mutant mice covered less than half the distance explored
by wild-type mice at 5 weeks of age (Fig. 3A). Mice treated with AAV8-
Mtm1 at both early and late stages of the disease showed significant
functional improvement, and at 6 months after AAV injection, their
motor activity was indistinguishable from that of wild-type animals. A
noninvasive test of global muscle strength that measures forward
pulling tension in an escape paradigm revealed that untreated Mtm1-
deficient mice were half as strong as wild-type mice (whole-body ten-
sion, 0.07 ± 0.01 versus 0.15 ± 0.01 N/g; P < 0.01) (Fig. 3B). Early- and
late-treatedmice showed82% (0.15± 0.01N/g) and76% (0.13± 0.01N/g)
recovery of whole-body tension, respectively (Fig. 3B). In a functional
assay of an isolated hindlimb muscle, the extensor digitorum longus,
the isometric force of untreated Mtm1 KO mice was only 13% of
the wild-type level, whereas it almost normalized 6 months after AAV8-
Mtm1 delivery in both cohorts (P = 0.0016 and P < 0.001 for the early-
and late-treated groups of mice, respectively; Fig. 3C). Together, these
data indicate that muscle impairment associated with myotubularin
deficiency can be rescued by gene therapy even after the onset of
pathology.
Correction of muscle pathology in myotubularin-deficient
mice is dose-dependent
To assess the effect of a lower vector dose on phenotype correction,
we injected AAV8-Mtm1 (5 × 1012 vg/kg) into the tail vein ofMtm1
KOmice at 3 weeks of age (n = 10). This dose prolonged the survival
of 50%of themice over 3months, with the first death occurring 6weeks
after injection (fig. S3A). Body weight increased during the first 3 weeks
of treatment and remained unchanged after this period (fig. S3B). This
partial recovery of body mass was reflected at the level of individual
skeletal muscles: two of the seven analyzed muscles (soleus and biceps
brachii) grew normally, whereas the other five reached 40 to 60% of
wild-typemass at 3months (fig. S3C). Themotor activity of mice treated
with the low vector dose appeared indistinguishable from that of wild-
type mice and KO mice treated with the high dose in an open-field
actimeter assay 3months after injection (fig. S3E).However, their global
muscle strength was reduced by 55% in the more sensitive escape test,
and their isolated soleus and extensor digitorum longus muscles gener-eTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 2
R E S EARCH ART I C L Eated 60 and 9% of the wild-type force, respectively, indicating that
muscle function recovery was not complete in the low-dose cohort.
In the extensor digitorum longus muscle, only 3% of the myotubularinwww.Sciencendogenous level was reached (fig. S3D), ranging from 7 to 27% in the
other analyzed muscles (mean = 13%), indicating that low levels of
MTM1 are sufficient to prolong the survival of mutant mice. 
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 Fig. 1. Intravascular delivery of AAV8-Mtm1 in myotubularin-deficient
mice improves life span and body growth. (A) Experimental design. (B
AAV8-Mtm1 (KO Early + AAV, n = 8; KO Late + AAV, n = 8). Values were
normalized to muscle mass of age-matched, saline-injected WT mice (n =and C) Survival (B) and body mass (C) of wild-type (WT) mice and
constitutive KO-Mtm1 mice injected at 3 weeks of age with saline (WT +
saline, KO+ saline, n= 10 per genotype). Myotubularin-deficientmicewere
injected with AAV8-Mtm1 at 3 × 1013 vg/kg at 3 (KO Early + AAV, n = 8) and
5 weeks of age (KO Late + AAV, n = 11) in a 6-month study. (D) Mass of
representative skeletal muscles of KO-Mtm1 mice 2 weeks after injection
of saline (KO + saline, n = 4) and 6 months (n = 10) after injection of10), taken as 100%. (E) Myotubularin protein quantification by immunoblot;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) immunodetection
was used as an internal control. Thenumber of animalswas as in (C).Muscles:
TA, tibialis anterior; EDL, extensor digitorum longus; SOL, soleus; GA, gas-
trocnemius; QUA, quadriceps; TRI, triceps; BI, biceps brachii; DIA, diaphragm.
*P < 0.05; **P < 0.01; ***P < 0.001, Mann-Whitney test, each condition versus
WT + saline values.eTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 3
R E S EARCH ART I C L E
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Fig. 2. Mtm1 gene therapy corrects the internal architecture and hy-
potrophy of skeletal muscle fibers in myotubularin-deficient mice.
and NADH-TR and by immunofluorescence with antibodies against DHPR1a
and dysferlin. White arrows indicate abnormal localization of proteins. ScaleTreatment groups were as described in Fig. 1. Myotubularin-deficient mice
were injected with AAV8-Mtm1 at 3 × 1013 vg/kg at 3 (KO Early + AAV, n = 8)
and 5 weeks of age (KO Late + AAV, n = 11) in a 6-month study. Mice were
injected with either saline (+ saline) or AAV8-Mtm1 vector (+ AAV). Sections
were obtained after 2 weeks (5 weeks of age) and after 6 months of treat-
ment. (A) Cross sections from tibialis anterior (TA) muscle stained with H&Ewww.Sciencbars, 10 mm. (B) Mean diameter of muscle fibers from tibialis anterior and
biceps brachii muscles from mice injected with either saline or AAV8-Mtm1
after 2 weeks (left graph; WT + saline, n = 10; KO + saline, n = 4) and after 6
months of treatment (right graph; WT + saline, n = 10; KO Early + AAV, n = 7;
andKOLate +AAV, n=8). **P<0.01; ***P<0.001, t test, each condition versus
WT + saline values.eTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 4
R E S EARCH ART I C L E
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01
4Intramuscular injection of AAV8-MTM1 ameliorates
pathology and increases strength of myotubularin-deficient
canine muscles
To evaluate myotubularin gene replacement therapy in a large-animal
model, we studied male XLMTM Labrador/Beagle F1 offspring, which
display the same pathology and clinical features as the previously re-
ported XLMTM pure-bred Labradors (15). These dogs become symp-
tomatic by 9 to 10 weeks of age, and muscular weakness progresses up
to ~18 weeks of age, when animals can no longer ambulate and rapidly
die. For this study, we generated a recombinant AAV8 vector carrying
the canineMTM1 cDNA under the control of the desmin promoter as
in the murine vector (AAV2/8-pDesmin-MTM1 or AAV8-MTM1).
The vector was produced in Sf9 cells by a baculovirus-based system,
purified by affinity chromatography, and formulated for in vivo injec-
tion. To assess transgene expression and the local effect on diseased
muscle, we injected a single dose of 4 × 1011 vg of the AAV8-MTM1
vector into the middle part of the cranial tibialis hindlimb muscle of
XLMTM dogs at 10 weeks of age (n = 3). The contralateral muscles re-
ceived only saline. Dogs were sacrificed after 4 to 6 weeks, and injectedwww.Scienc
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 muscles were analyzed for histological appearance, protein expression,
and function. All AAV-treated muscles grew in mass and volume by
about 50% compared to the contralateral, saline-injected muscles, as
shown by weight/volume measurements and computed tomography
scans (Fig. 4A and fig. S4). AAV-injected muscles consistently showed
improved architecture, with increased myofiber size, normalization of
mitochondria positioning, and cellular localization of DHPR1a and
dysferlin (Fig. 4C). Electron microscopy confirmed that, compared to
wild-type muscle, XLMTMmuscle contained few characteristic T-tubules
but showed atypical longitudinal structures (L-tubules). By contrast,
AAV8-MTM1–injected mutant muscles closely resembled wild type, with
abundant T-tubules (Fig. 4C and table S1). Expression of vector-driven
MTM1 protein was analyzed on whole-muscle lysates by Western
blotting with an antibody against canine myotubularin. Immunoblot
analysis showed substantial myotubularin expression in the injected
muscles of all treated dogs (Fig. 4A), decreasing from about 60% of
the wild-type levels at the center of the cranial tibialis to about 8% at
its ends. Some myotubularin expression was detected in the contig-
uous extensor digitorum longus muscles, whereas no expression was
detected in the contralateral limb muscles or in distant muscles such
as the diaphragm or the heart.
To evaluate the effect of treatment onmuscle function, we used force
transduction assays developed to assess the strength of the distal part of
canine hindlimbs during flexion,mainly generated by the cranial tibialis
muscle (Fig. 4B depicts an isometric contraction assay) (19–21). Imme-
diately before gene therapy at 10 weeks of age (baseline), XLMTM dogs
were slightly weaker than unaffected wild-type littermates, and the two
hindlimbs of each dog performed equally (Fig. 4B). Measurements of
force 4 and 6 weeks later showed more than doubled limb strength in
wild-type dogs, consistentwith normalmuscularmaturation. Inmutant
dogs, the strength of AAV8-MTM1–treated limbs increased strikingly
only 4weeks after injection and reached 80%ofwild-type force at 6weeks,
whereas limbs injected with saline did not improve. We also used a
dynamic eccentric contraction assay to measure muscular performance
over prolonged exercise (fig. S5). When assessed by this test, the hind-
limbs of young wild-type dogs strengthened over time, whereas saline-
injected limbs of all three XLMTM dogs declined to about 20% of
wild-type values. Again, injection of AAV8-MTM1 greatly improved
muscle performance: at 14 and 16 weeks of age, treated limbs achieved
>70% of wild-type strength (fig. S5, B to D). These results showed that a
single injection of AAV8-MTM1 is efficacious in rescuing the function of
an entiremyotubularin-deficientmuscle, prompting us to assess an intra-
vascular delivery approach.
Intravascular administration of AAV8-MTM1 rescues muscle
pathology and prolongs survival of XLMTM dogs
AAV delivery by isolated limb perfusion allows widespread transduc-
tion of muscle groups in dogs and nonhuman primates (22–24). To test
whether regional administration is sufficient to ameliorate muscle pa-
thology in an entire limb, we injected a single dose of AAV8-MTM1
(2.5 × 1013 vg/kg) under high pressure into the saphenous vein of three
9-week-old XLMTM dogs, after applying a tourniquet around the hind-
limb distal to the injection site to limit blood circulation during infusion.
The tourniquet was released 5 min after injection. Treated dogs improved
in strength rapidly after vector administration. In contrast to dogs injected
intramuscularly,where only themuscles of the injected limbgained strength,
high-pressure intravascular limbdelivery ofAAV8-MTM1 resulted in im-
proved strength of both the infused and contralateral hindlimbs, whichFig. 3. Gene therapywith AAV8-Mtm1 improves strength, activity, and
long-termsurvival inmyotubularin-deficientmice. (A)Whole-body spon-
taneousmobility ofnormal (WT+saline),mutant (KO+saline), andAAV-treated
mutant (KO Early + AAV and KO Late + AAV) mice 2 weeks (5 weeks of age)
and 6 months after phosphate-buffered saline (PBS) or vector injection. The
distance covered over the 90-min test was assessed with an open-field
actimeter. (B) Escape test measurements in the same five groups of mice
(WT + saline and KO + saline at 5 weeks; WT + saline, KO Early + AAV, and
KO Late + AAV at 6 months). (C) Specific tetanic force of isolated extensor
digitorum longus muscles from KOmice injected at an early and late stage
of the disease 6months after vector delivery compared to saline-injected KO
and WT littermates. WT + saline (n = 6) and KO + saline (n = 4) at 5 weeks;
WT + saline (n = 10), KO Early + AAV (n = 8), and KO Late + AAV (n = 8) at
6 months. *P < 0.05; **P < 0.01; ***P < 0.001, t test.eTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 5
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Fig. 4. Myotubularin is expressed and increases muscle mass and volume after local
gene therapy inXLMTMdogs. (A) Cranial tibialis caninemuscles 6weeks after AAV8-MTM1
intramuscular injection. Immunoblot of myotubularin (MTM1) and GAPDH from cranial
tibialis muscle lysates at proximal, middle, or distal sections of the muscle. (B) MTM1
gene replacement therapy increases hindlimb strength in XLMTM dogs. The drawing
shows the method used to measure hindlimb flexion strength in dogs. A nerve stimulatorelivers electrical frequencies from 1 to 110 Hz to muscles that pull the paw toward the stifle (knee). A transducer captures the torque generated when the
aw pulls on the foot pedal. Upper graph: baseline before injection, 10 weeks of age (WT, n = 3; XLMTM, n = 3); middle graph: 4 weeks after injection, 14 weeks
f age (WT,n=3; XLMTM,n=3); bottomgraph: 6weeks after injection, 16weeks of age (WT,n=2; XLMTM,n=2). P=0.002 (4weeks after injection); P=0.0161
weeks after injection; XLMTM + AAV versus WT + saline values), one-way analysis of variance (ANOVA). (C) Local myotubularin gene replacement therapy im-
rovesmuscle fiber architecture inXLMTMdogs. Cryosectionsof the cranial tibialismuscle (middlepart)were assessedmicroscopically: boxes inNADH-TR staining
ow areas magnified below; immunofluorescence staining for DHPR1a and dysferlin shows correction of abnormal organelles with AAV8-MTM1 (yellow
rrow). Scale bars, 25 mm. Electronmicroscopy (EM) shows normal T-tubules (black arrows) and abnormal L-tubules (white arrow). Scale bar, 500 nm. Bottom
panel: Close-up ofWTmuscle and schematic showing normal relationship of sarcomere ends (Z-line), and triads of T-tubules and sarcoplasmic reticulum (SR).www.ScienceTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 6
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 reached on average almost normal values 6 weeks after infusion (Fig. 5A
and fig. S6). Similarly, peak inspiratory flow (PIF) (the fastest flow rate
measured during inhalation) was strongly reduced in XLMTM dogs at
16 weeks of age, but was normal in treated dogs (Fig. 5B), indicating that
the AAV8-MTM1 vector transduced respiratory muscles and improved
their function. Most importantly, all treated dogs showed a marked im-
provement in survival, which extended far beyond the critical 18-week
time point, when all untreated XLMTM dogs could no longer ambulate
and needed to be euthanized. The first infused XLMTMdog (dog 4) sur-
vived in relatively good condition beyond 1 year and was sacrificed for
analysis at 14months of age. The other two dogs (dogs 5 and 6) remained
ambulant and clinically robust beyond the age of 1 year, and were alive
and healthy at the time of manuscript preparation (movie S2).
Muscle biopsieswere taken from the injected and contralateral hind-
limbs (quadriceps and biceps femoris) and from the forelimbs (triceps
and biceps brachii) of all treated dogs 4 weeks after infusion to analyze
vector distribution, transgene expression, and histology. Intravenous
administration of AAV8-MTM1 improved myofiber appearance and
architecture in the treated limbs, which consistently showed an average
fiber size only slightly reduced compared to wild-type muscles
measured 4 weeks after infusion (Fig. 6A). In contrast, at 1 year after
infusion, noninfused limbs displayed heterogeneity in muscle fiber size,
with coexistence of small and large fibers (Fig. 6B). Electronmicroscopy
performed on quadriceps muscle samples obtained from all infused
limbs showed normalized sarcotubular organization, similar to what
was observed after intramuscular injection (table S2). The biceps fe-
moris muscles of dog 4, analyzed at sacrifice, revealed a partially defec-
tive sarcotubular organization in both the infused and noninfused
hindlimb, with only about one triad per field in each muscle (table S3).
Real-time polymerase chain reaction (PCR) andWestern blot anal-
ysis demonstrated both AAV8 vector (Fig. 7A) andmyotubularin (Fig. 7B
and fig. S7) expression in allmuscle samples obtained fromall three treated
dogs: 4 weeks after infusions, the level of myotubularin expression reached
21 to 72% of the wild-type control levels in the biceps femoris and quad-
riceps muscles in the injected limbs and 9 to 138% in the muscles (quad-
riceps, biceps femoris, triceps, and biceps brachii) of the noninjected limbs.
Expression levelswere paralleled byVCN levels, which ranged from0.52 to
2.35 in the biceps femoris and quadricepsmuscles of the infused limbs and
from 0.17 to 3.65 in the muscles of the noninjected limbs (Fig. 7A). The
biodistribution of AAV8-MTM1 was analyzed in dog 4 at necropsy. The
VCN was, in general, higher in infused muscles (range, 0.01 to 2.27)
than in distal muscles (range, 0.007 to 0.13; n = 18), with the exception
of the diaphragm, intercostal muscles, and heart, where we detected a
VCNof 0.37, 0.59, and 0.28, respectively (Fig. 7C).MTM1protein levels
were above the endogenous level in 7 of 13 muscles from the infused
hindlimb and barely detectable in the contralateral and forelimb mus-
cles (Fig. 7D), mirroring the VCN values and suggesting that very low
amounts of myotubularin are sufficient to rescue muscle function. In
the diaphragm and heart, myotubularin reached 64 and 13% of the
wild-type values, respectively. The heart of dog 4 showed no signs of
toxicity at histological examination (fig. S8) and at the functional level,
as assessed by electrocardiogram and echocardiography before necropsy.
Thehistologyof the liver (VCN: 0.63)was alsonormal, andmyotubularin
protein was undetectable.
These data show that isolated limb perfusion was effective in de-
livering the AAV vector to the infused muscle groups but did not limit
vector diffusion to other organs, including the rest of the skeletal mus-
culature and the heart.www.SciencIntramuscular or intravascular delivery of AAV8-MTM1 elicits
no humoral or cytotoxic immune response against the
transgene product in XLMTM dogs
The neutralizing factor (NAF), immunoglobulin G (IgG), and IgM ti-
ters specific to AAV8 were measured in XLMTM dog sera before and
after intramuscular (fig. S9A) or intravascular (fig. S9B) administration
of AAV8-MTM1. NAF and IgG titers increased 1 week after injection
and remained elevated for up to 10months in all treated animals, whereas
IgM titers decreased to preinfusion levels in dogs treated by intravascular
infusion. Conversely, MTM1-specific IgG or IgM antibodies remained
undetectable in all treated animals (fig. S9, C and D). Cell-mediated im-
mune responses against the vector or the transgene product were tested
by an interferon-g (IFN-g) enzyme-linked immunospot assay on periph-
eral blood mononuclear cells over a period of 155 days after vector ad-
ministration. We were unable to detect any T cells specific to the vector
capsid or the MTM1 protein in XLMTM dogs given intramuscular or
intravenous AAV8-MTM1 (fig. S10).
Inflammatory cytokines [interleukin-2 (IL-2), IL-6, IL-8, IL-10, IL-15,
tumor necrosis factor–a (TNF-a), and IFN-g] were profiled in XLMTM
dogs before and after intramuscular or intravascular infusion of AAV8-
MTM1 (table S4). Of the three dogs injected intramuscularly, one (dog 3)
displayed elevated TNF-a levels (42.5 to 80.8 pg/ml) between day 3 and
day 28 after injection. Transient elevation of IL-2 and IL-15 levels (743.5
and 119 pg/ml, respectively) was observed in only one dog treated intra-
vascularly (dog 6) 6 hours after infusion. No elevation of inflammatory
cytokines levels was observed in the other animals, including untreated
controls, throughout the observation period.DISCUSSION
Gene therapy of neuromuscular disorders requires body-wide distribution
of the therapeutic gene and, therefore, systemic delivery of a gene transfer
vector capable of transducing skeletalmuscles and, if necessary, the heart.
AAVvectors are attractive candidates because of their natural tropism for
muscle and their small size, which allows access to fibers through the vas-
cular endothelium and the basement membrane. Preclinical and clinical
studies proved that AAV-mediated delivery can lead to transgene expres-
sion at therapeutic or subtherapeutic levels in entiremuscles and can cor-
rect the disease phenotype in animal models of muscular dystrophy
[reviewed in (25)]. Clinical trials showed, however, that intramuscular
injection is impractical and unlikely to provide significant clinical benefit
to patients affected by limb girdle or Duchenne muscular dystrophy
(DMD) (5–8). Initial efforts aimed at targeting skeletal and cardiac
muscles through intravascular delivery required the use of invasive pro-
cedures and relatively toxic permeabilizing drugs (26). However, the in-
troduction of muscle-tropic serotypes such as AAV6, AAV8, and AAV9
allowed the transduction of both skeletal and cardiac muscle by low-
pressure intravascular or systemic intravenous administration, and achieved
significant phenotypic correction in both murine and canine models of
muscular dystrophy (27–30). Systemic AAV administration has not yet
been attempted in patients.
Here, we show long-term full phenotypic correction of MTM1-
deficientmyotubularmyopathy in both amurine and a caninemodel of
the disease by intravenous administration of an AAV8 vector carrying a
muscle-specificMTM1 expression cassette. Inmice, a single tail vein ad-
ministration of theAAV8-Mtm1 vector either before or after the onset of
the pathology achieved full rescue of the disease for the duration of theeTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 7
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 Fig. 5. Hindlimb strength of XLMTM dogs after intravascular admin-
istration of AAV8-MTM1. Data are presented as means ± SD combined
23 weeks of age (WT, n = 3; XLMTM + AAV8, n = 3). XLMTM dogs infused
only with saline did not survive beyond 18weeks of age. (F) One year aftervalues of both limbs. (A) Peak hindlimb torque at various times up to
1 year after infusion. (B) Baseline before infusion, 9 weeks of age (WT, n =
2; XLMTM + AAV8, n = 3; XLMTM + saline, n = 1). (C) Six weeks after in-
fusion, 15 weeks of age (WT, n = 2; XLMTM + AAV8, n = 2; XLMTM + saline,
n = 2). (D) Eight weeks after infusion, 17 weeks of age (WT, n = 3; XLMTM+
AAV8, n = 3; XLMTM + saline, n = 3). (E) Fourteen weeks after infusion,www.Sciencinfusion (WT, n = 1; carrier, n = 3; XLMTM + AAV8, n = 3). (G) PIF, a respi-
ratory functional measure reflecting diaphragmmuscle strength, taken in
anesthetized dogs at baseline and at 8 weeks, 14 weeks, and 1 year after
infusion with AAV8. Number of animals per group was the same as in (B)
to (F). ***P < 0.001, one-way ANOVA, each condition versus WT + saline
values.eTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 8
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 Fig. 6. MTM1 gene therapy corrects the internal architecture and hy-
potrophy of skeletal muscle fibers in myotubularin-mutant dogs.
from muscle biopsies taken 4 weeks after infusion from dog 4 stained
with H&E or NADH-TR. (B) H&E-stained cranial tibialis muscle cross sectionsMuscle cryosections from age-matched WT or AAV8-MTM1–infused
XLMTM dogs were assessed microscopically. Comparison is shown be-
tween the left (infused) hindlimb and the right (contralateral noninfused)
limb. (A) Representative micrographs of quadriceps muscle cross sectionswww.Scienctaken 1 year after AAV infusion. Graphs indicate myofiber diameter fre-
quency distribution of corresponding images for the vastus lateralis
muscle (upper graph) and craniotibialis muscle (lower graph). Scale bars,
25 mm.eTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 9
R E S EARCH ART I C L Estudy. The fact that the MTM1 pathology could be corrected in already
severely affected mice indicates that the damage induced by the absence
ofMTM1 is reversible, a particularly important finding in view of a clin-
ical translation of XLMTM gene therapy, which will inevitably involve
already symptomatic patients. However, differences exist between the
clinical presentation of XLMTMinpatients compared to animalmodels.
In particular, patients typically present with respiratory failure at birth,
whereasmice and dogs develop respiratoryweakness later in life. Thus, it
may be necessary to develop specific clinical protocols for treating very
young children and balance the risk of treatment versus that of assisted
ventilation.
To confirm the therapeutic potential of the AAV8-MTM1 vector in
the XLMTM dogmodel, we decided to use a clinically relevant delivery
method based on isolated limb perfusion. This delivery route showed
feasibility and safety in a clinical trial on volunteer patients affectedwww.Scienceby several forms of muscular dystrophy (31). We intended to use high-
pressure intravascular hindlimb administration as an intermediate ap-
proach between direct intramuscular muscle injection, which confirmed
the therapeutic potential of the AAV8-MTM1 vector even in large
muscles, and full systemic administration. Surprisingly, we observed a
marked rescue of the lethality and a systemic correction of the skeletal
muscle pathology in all treateddogs throughout thedurationof the 1-year
study. Intravascular delivery of the AAV8-MTM1 vector under pressure
against a tourniquet led to efficient transduction not only of allmuscles in
the infused limb but also of distalmuscles and organs, although at a lower
level in terms of both VCN and protein expression. The respiratory
muscles, and particularly the diaphragm, were well transduced and their
function was normalized in all animals. This is the first demonstration
of complete and persistent phenotypic correction of a monogenic
neuromuscular disease in a large-animal model by a single intravenous 
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 Fig. 7. Biodistribution of AAV8 vector and myotubularin transgene ex-
pression in XLMTMdogs infusedwith AAV8-MTM1. (A and B) Comparison
myotubularin antibody. (C and D) Comparison of vector distribution (C) and
MTM1 transgene expression (D) amongupper and lower limbmuscle necrop-of vector distribution (A) and MTM1 transgene expression (B) among upper
and lower limb muscle biopsies collected 4 weeks after infusion in three
XLMTMdogs: dogs 4 to 6. Upper limbmuscles: triceps (TRI) and biceps brachii
(BI bra). Lower limbmuscles: biceps femoris (BI fem) and quadriceps (QUA). R,
right; L, left; inf, infused limb. (B) Expression of canineMTM1protein relative to
the housekeeping gene GAPDH in whole-muscle lysates probed with an anti-sy samples collected 1 year after infusion in dog 4, an XLMTMdog. Muscles of
the infused leg: VL, vastus lateralis; VM, vastus medialis; RF, rectus femoris; Ad,
adductor magnus; Pec, pectineus; Sar, cranial sartorius; Gra, gracilis; BI fem, bi-
ceps femoris; ST, semitendinosus; SM, semimembranosus; CT, cranial tibialis;
Gast, gastrocnemius; Per, peroneus longus. Muscles distal to the infused leg:
Dia, diaphragm; Interc, intercostals; He, heart.TranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 10
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 administration of an AAV vector. Our results indicate that systemic in-
travenous administrationmay be the simplest andmost effective way of
administering an AAV-based gene therapy for XLMTM in patients, al-
though additional dose-finding and toxicity studies will be necessary
before launching a clinical trial.
The unpredicted systemic effect of the high-pressure intravascular
vector administration in the present study is in contrast with previous
studies of tightly restricted vector transduction in the limbs of hemo-
philic and golden retriever muscular dystrophy (GRMD) dogs, infused
with AAV1 or AAV2 vectors (24, 32). Although blood flow was mon-
itored in the present study by ultrasound above and below the con-
striction during infusion, the tourniquet was apparently inefficient in
limiting vector delivery to the infused limb because of slippage, collateral
circulation, or other less obvious factors. The tourniquet was released af-
ter 5min,when a substantial amount of vectorwas apparently still avail-
able to enter the systemic circulation and transduce distant organs. A
longer persistence of the AAV8 with respect to an AAV1 or AAV2
vector in the isolated limb circulation might have also contributed to
the ineffective restriction. The gradient of VCN distribution above
and below the tourniquet was more pronounced in the first treated
dog, dog 4, than in the subsequent two, dogs 5 and 6, where the vector
transduced almost uniformly all muscles, indicating a certain variability
in the limb isolation procedure.
The quasi-systemic vector administration was well tolerated by all
threeXLMTMdogs, which showedno signs of acute or chronic toxicity.
Liver enzyme levelswerewithin the normal range in all dogs throughout
the study, and the histology of dog 4’s liver appeared to be normal at
necropsy. Likewise, no toxicity was observed in the systemically treated
mutant mice, with the exception of focal heart inflammatory infiltrates
and fibrotic lesions detected in animals treated at the highest dose (3 ×
1013 vg/kg), but otherwise asymptomatic. This was not observed in the
heart of dog 4 at necropsy, which was completely normal 1 year after
vector administration. The desmin promoter is very active in cardiac
muscle (33) and caused a marked MTM1 overexpression in murine
heart. Conversely, MTM1 expression was below the endogenous level
in the heart of dog 4, which was treated with a similarly high dose com-
pared to the mouse study (2.5 × 1013 vg/kg), although through a differ-
ent route. This suggests that accessibility from the systemic circulation,
heart tropism of the AAV8 vector, or desmin promoter function may
vary among different species, and indicates the need for a specific tox-
icity study in large animals before advancing to a clinical trial.
Our study shows that the threshold of myotubularin expression re-
quired for therapeutic benefit in XLMTMmice and dogs is well below
the normal levels and may vary among different muscles, as observed
for other neuromuscular disorders because of enzyme rather than struc-
tural protein deficiency (34). InMtm1 KOmice, administration of low
levels of an engineered myotubularin protein was sufficient to improve
both muscle function and pathology (35). In other studies, mice
carrying an engineered Mtm1 missense mutation that affects RNA
splicing and leaves just traces of myotubularin activity survive eight
times longer than constitutiveMtm1KOmutants (36). Here, the amount
of myotubularin present in skeletal muscles of mice 6 months after high-
dose vector injection ranged between one and five times the endogenous
levels, leading to full correction. A lower vector dose led to synthesis of 3
to 27% of the normal myotubularin levels in treated mice, which was cu-
rative for somebut not allmuscles butwas still able to prolong survival. In
dogs, the vector-derived myotubularin level in skeletal muscles was also
variable and, in general, higher in the infused limb. In dog 4, where dif-www.Scienceferences between the infused and noninfused limbs were more
pronounced, functional reconstitution was observed even in muscles
where myotubularin was barely detectable and the pathology was
not fully corrected. In the other two dogs, dogs 5 and 6, the levels of
myotubularin were higher in all muscles (30 to 140% as measured in
biopsies) and led to an objectively better phenotypic correction in the
whole body. Respiratory function was normalized in all three dogs.
Lower than normal levels of myotubularin are therefore sufficient to
ameliorate muscle function even in the presence of incomplete restora-
tion of the histology, and a dose of ~2 × 1013 vg/kg was fully therapeutic
in both animal models of the disease. Even though comparing doses in
different studies is a difficult exercise, the results of a recent clinical
study on the systemic administration of anAAV8 vector expressing hu-
man factor IX in hemophilia B patients suggest that a dose of 1013 vg/kg
may be administrable to XLMTM patients, possibly in combination
with transient immunosuppression (4, 37).
In contrast to previous observations in animalmodels ofDMD(24, 38),
our data demonstrate relatively long-term expression of AAV-derived
myotubularin in muscles of XLMTM mice and dogs treated with a
single dose of recombinant vector. A major difference between DMD
andXLMTM is that the pathology ofmyotubularin-deficientmuscles is
not per se associated with inflammation or with the cycles of degener-
ation/regeneration typical of dystrophic muscles (13, 15, 39). The cor-
rection of pathology observed for XLMTM is unlikely to occur in the
advanced stages of dystrophic myopathies like DMD, where muscle fi-
bers degenerate and are irreversibly replaced by fat and fibrotic tissue.
Notably, we observed no humoral response against MTM1 or cellular
immune response against either the vector or MTM1, highlighting ma-
jor differences in the vector-host interactions in the case of nondys-
trophic muscle pathology. Normal skeletal myofibers are long-lived,
and transgene expression can persist up to 10 years in human skeletal
muscle after AAV-mediated gene transfer (40). We can therefore pre-
dict that in the absence of inflammatory, humoral, or cytotoxic immune
responses, vector-derived MTM1 expression could persist for many
years inmuscles of XLMTMpatients treated by gene therapy. The pres-
ence of residual levels ofmyotubularin, as observed in the canine animal
model, will probably be a decisive factor in limiting the risk of adverse
immune reactions.
In conclusion, our results demonstrate that intravenous AAV8-
mediated gene therapy leads to long-term systemic correction of
XLMTM in small- and large-animal models at doses compatible with
clinical application, and pave the way to a clinical trial of gene therapy
for myotubular myopathy.MATERIALS AND METHODS
Study design
Predefined study components. Preliminary data indicated that
six animals were required in each group to detect a 20% difference in
muscle strength with 80% power, and an a of 0.05. No animals were
excluded from analysis.
Rationale and design of study. This was an early-stage observa-
tional study designed to search for possible differences among experi-
mental treatment (gene replacement) groups. Animals were assigned to
treatment groups on the basis of availability of gene replacement vector.
For mouse experiments, the primary endpoint was survival; for dogs,
the primary endpoint was muscle strength.TranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 11
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 Randomization and blinding. This was an open-label and non-
randomized study. For dogs, functional data were analyzed by an inves-
tigator (J.A.D.) blinded to the intervention.
Replication. Repeated functional measures were conducted over
time in animals as indicated. Technical replicates were performed in
PCR, Western blot, and immunological assays.
Animals
Mice were handled according to French and European legislation on
animal care and experimentation and approved by the institutional eth-
ical committee. The constitutiveKOof themyotubularin gene (KO-Mtm1,
also named BS53d4-129pas) was described previously (13, 18). Wild-type
littermate males were used as controls.
Dogs were handled according to principles outlined in the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals. XLMTM dogs were described previously (15). Affected males
were identified by PCR-based genotyping, as described.
Construction and production of AAV8-MTM1 vectors
The recombinant adeno-associated virus vector AAV2/8-pDesmin-
Mtm1murine (designated AAV8-Mtm1) was constructed as follows.Mu-
rine Mtm1 cDNA [AF073996, National Center for Biotechnology
Information (NCBI)] was cloned downstream of the human desmin
promoter in the AAV2 expression plasmid pAAV2-pDes by PCR
amplification. Pseudotyped recombinant AAV2/8 viral preparations
were generated by packaging AAV2-inverted terminal repeat recombi-
nant genomes into AAV8 capsids using a tritransfection protocol as
previously described (17). Viral titers were quantified by a TaqMan
real-time PCR assay (Applied Biosystems) and expressed as viral ge-
nomes per milliliter (vg/ml).
The recombinant adeno-associated virus vector AAV2/8-pDesmin-
MTM1canine containing a canine myotubularin cDNA regulated by
the desmin promoter (designated AAV8-cMTM1) was produced in a
baculovirus/Sf9 system (41). Two baculovirus batches were generated:
one expressing rep and cap AAV genes and the second bearing the
canineMTM1 cDNA (XM850116, NCBI) downstream from the human
desmin promoter. The AAV8-cMTM1 vector particles were produced
after baculoviral double infectionof insect Sf9 cells andpurified from total
cell culture with AVB affinity chromatography column (GE Healthcare,
AVB Sepharose high performance). The concentration in vg/ml was
determined from deoxyribonuclease-resistant particles by a TaqMan
real-time PCR assay (Applied Biosystems). Other routine quality control
assays for recombinant AAV vectors were performed, including sterility
and purity tests.
Administration of AAV8-MTM1 vectors
Systemic vector administration in mice. AAV8-Mtm1 at 3 ×
1013 vg/kg was injected into the tail vein of 3- and 5-week-old KO-
Mtm1mice. An equivalent volume of saline was administrated to either
KO-Mtm1 or wild-type animals as controls.
Intramuscular delivery in dogs. AAV8-cMTM1 (4 × 1011 vg)
diluted in 1 ml of lactated Ringer’s solution was injected under ultra-
sound guidance into the midbelly of the cranial tibialis muscle of one
hindlimb of unvaccinated 10-week-old affectedmale XLMTMdogs un-
der anesthesia. The cranial tibialis muscle of the contralateral limb was
injected with an equal volume of Ringer’s solution alone. Unaffected
male littermates (wild type) received 1 ml of Ringer’s solution in each
hindlimb.www.ScienceHigh-pressure intravascular limb infusion. In anesthetized
XLMTM dogs, AAV8-cMTM1 (2.5 × 1013 vg/kg) diluted in PBS was
infused into the distal saphenous vein under pressure (300 torr) against
a tourniquet as described (42). Briefly, a tourniquet was positioned at
the level of the groin and adjusted until the femoral pulse was no longer
detectable by ultrasound, to transiently block blood inflow to the target
limb. Vector was suspended in PBS at 20% of the total hindlimb volume
(determined by water volume displacement) and administered via a
14-gauge catheter placed into a distal branch of the peripheral saphenous
vein on the dorsum of the paw. The tourniquet was tightened for a total
of 15 min (10 min before and 5 min during the infusion). In each dog,
one hindlimb was infused with vector, whereas the contralateral hind-
limb was not infused. For vector copy and immunoblot analysis, the
midsection of the muscle belly was sampled at biopsy or necropsy.
VCN analysis
The number of vector genomes per diploid genomewas quantified from
80 ng of total DNA by TaqMan real-time PCRwith a 7900HT thermo-
cycler (Applied Biosystems). The canine b glucuronidase gene was used
for standardization. The primers and probe used for vector genome
(MTM1) amplification were as follows: 5′-ATAAGTTTTGGACA-
TAAGTTTGC-3′ (forward), 5′-CATTTGCCATACACAATCAA-3′
(reverse), and 5′-CGACGCTGACCGGTCTCCTA-3′ (probe). The
primers and probe used for b glucuronidase amplification were as
follows: 5′-ACGCTGATTGCTCACACCAA-3′ (forward), 5′-CCCCA-
GGTCTGCTTCATAGTTG-3′ (reverse), and 5′-CCCGGCCCG-
TGACCTTTGTGA-3′ (probe) (Applied Biosystems).
Quantitative immunoblot analysis
Several muscle cryosections of 30 mm each (300 mm to 1 mm in total)
were sliced, and proteins were extracted and analyzed by SDS–
polyacrylamide gel electrophoresis and Western blotting as previously
described (16). Membranes were probed with either a polyclonal anti-
body against the C-terminal part of murine myotubularin [R2348 (17)]
or a rabbit polyclonal antibody raised against the C terminus of canine
myotubularin (R1040, Généthon). A mouse monoclonal antibody
specific for GAPDH (Millipore, MAB374) was used as internal con-
trol. Detection was performed with a secondary antibody coupled to
IRDye 680 (LI-COR) and theOdyssey infrared imaging system (LI-COR
Biotechnology Inc.).
Histological and immunofluorescence analyses
Histology and morphometry. For mouse studies, cryosections
(7mm)of frozenmuscleswere processed forH&EandNADH-TR stain-
ings using standard procedures. The proportion of internalized nuclei and
the diameter of myofibers were quantified as previously described (16).
For canine studies, serial 8-mm-thick transverse cryosections were
prepared from frozen muscles and processed for H&E and NADH-TR
stainings. The number of centrally nucleated fibers and fibers with mis-
localization of organelles (including mitochondrial aggregates and neck-
lace fibers) was quantified manually from photographs taken at ×200
magnification. For fiber size quantification,muscleswere immunostained
as described above with rabbit anti-dystrophin antibodies (Abcam PLC,
ab15277) and Alexa Fluor–conjugated anti-rabbit IgG (Molecular
Probes). Staining was evaluated, and MinFeret diameters of fibers were
quantified with a Nikon Eclipse 90i microscope with NIS-Elements AR
software (Nikon Instruments Inc.) and a BX53 microscope and cellSens
Standard software (Olympus). Slides for evaluation of canine cardiacTranslationalMedicine.org 22 January 2014 Vol 6 Issue 220 220ra10 12
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 pathology were produced through the Children’s Research Institute
Histology Core Facility at Medical College of Wisconsin (MCW). Elec-
tron microscopy was performed at MCW’s Electron Microscopy Core
Facility, and quantification of sarcotubular structures was performed as
described previously (35).
Immunofluorescence. For immunostaining of muscle tissue, fro-
zen transverse sections were fixed for 10 min by incubation in PBS at
100°C. Nonspecific antigens were blocked with PBS, 0.2% Tween, and
3% bovine serum albumin at room temperature. Sections were then in-
cubated at 4°C overnight with mouse primary antibodies directed
against DHPR1a (Thermo Scientific Pierce, MA3-920) or dysferlin
(Novocastra,NCL-HAMLET).After extensive PBSwashes, sectionswere
incubatedwithbiotinylated goat anti-mouse antibodies (SouthernBiotech)
and, after additional washes, with streptavidin conjugated with Alexa
Fluor 488 (Invitrogen). Glass slides were mounted with FluorSave re-
agent (Calbiochem,Merck) and visualized with a Leica confocal micro-
scope TCS-SP2. Digital images of a slice corresponding to the muscle
midsection were acquired with a charge-coupled device camera (Sony)
and a motorized stage.
Muscle function
Muscle function in mice.
Actimeter test. Spontaneous locomotor activity in mice was as-
sessed with the LE 8811 IR motor activity monitor (Bioseb). Briefly,
mice were placed in an open field bounded with 16 horizontal photo-
electric infrared beams to measure three-dimensional movements
of the animals. The distance crossed was recorded and analyzed for
90 min.
Escape test. Global strength of mice was evaluated as previously
described (43).Measurements of isometric contractile properties ofmu-
rine extensor digitorum longusmuscles were performed in vitro as pub-
lished (17).
Hindlimb contraction in dogs
Contractile properties in canine muscles in vivo were assessed as previ-
ously described (19, 20). Briefly, the hindlimb torque of anesthetized
dogs was measured by wrapping the foot to a pedal mounted on the
shaft of a servomotor that also functioned as a force transducer. Per-
cutaneous stimulation of the peroneal nerve activated hindlimbmuscles
to pull the foot up toward the body to generate torque. Isometric con-
tractions were performed over a range of stimulation frequencies to de-
termine torque-frequency relationships, and investigators blinded to the
experimental treatment analyzed the data.
Diaphragm muscle function in dogs
PIF was assessed under anesthesia by pneumatography as previously
described (44). Briefly, airflow was measured before the administration
of the centrally acting stimulant doxapram chloride (1.0 mg/kg) and
again after respiratory increase. Raw tracings were visually examined
to ensure complete capture of each breath before computer analysis.
Ten clear and successive breaths were selected from those collected at
baseline and again at the respiratory peak.
Statistical analysis
Statistical analyses were performed with SAS software (version 6; SAS
Institute Inc.). Individual means were compared with nonparametric
tests (Mann-Whitney, or Wilcoxon rank-sum and two-sided t tests).
Differences were considered to be statistically significant at P < 0.05 (*),www.ScienceP < 0.01 (**), or P < 0.001 (***). All data are presented as means ± SEM
unless stated otherwise.SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/6/220/220ra10/DC1
Immune response profile in XLMTM dogs
Fig. S1. Pathology of muscles from myotubularin-deficient mice at 3 weeks of age.
Fig. S2. Systemic gene replacement therapy ameliorates pathological hallmarks of myotubular
myopathy in skeletal muscles.
Fig. S3. Intravascular delivery of a lower dose of AAV8-Mtm1 in myotubularin-deficient mice
improves partially life span and body growth.
Fig. S4. Targeted myotubularin gene replacement therapy in XLMTM dogs increases the overall
size of injected muscles.
Fig. S5. Targeted gene therapy with AAV8-MTM1 injected into the cranial tibialis muscle
improves in vivo contractile response to repeated lengthening (eccentric) contractions in
XLMTM dogs.
Fig. S6. In vivo strength measured 1 year after regional hindlimb infusion of AAV8-MTM1 in an
XLMTM dog.
Fig. S7. Representative Western blot of myotubularin transgene expression in XLMTM dogs
infused with AAV8-MTM1.
Fig. S8. Necropsy findings in the heart of an XLMTM dog 1 year after AAV8-MTM1 infusion.
Fig. S9. Humoral response specific to AAV8 and myotubularin in XLMTM dogs.
Fig. S10. Cellular response to AAV8 or MTM1 protein in XLMTM dogs.
Table S1. Quantified histological findings in dogs after intramuscular injection.
Table S2. Quantified histological findings in dogs after intravenous AAV.
Table S3. Quantified histological findings in autopsy tissue at 1 year after infusion.
Table S4. Innate immune responses after intramuscular or regional limb administration of
AAV8-MTM1 in XLMTM dogs (dogs 1 to 6) and an untreated XLMTM dog (dog C).
Movie S1. Wild-type mouse (red tail) and myotubularin-deficient mouse (blue tail) treated with
AAV8-Mtm1 (3 × 1013 vg/ml) at 6 months after injection (note the robust appearance, normal
size, and activity of the treated Mtm1 KO mouse).
Movie S2. XLMTM dogs (dogs 4 to 6) treated with AAV8-MTM1, two untreated XLMTM dogs,
and a normal control dog at various times.REFERENCES AND NOTES
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